Worldwide Organ Transplantation Market Projected to Grow Radiantly By 2023 at CAGR of 9.8%; Asserts MRFR Unleashing Industry Forecast

“Organ Transplantation Market”
Market Research Future published a Half Cooked Research Report on “Global Organ Transplantation Market Research Report – Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

According to a recent study report published by the Market Research Future, The global organ transplantation market is booming and expected to gain prominence over the forecast period growing rapidly. The market is forecasted to demonstrate a spectacular growth by 2023.

Organ transplantation is one of the great advances in the modern day medicine and is a medical procedures in which an organ is removed from one body and transferred to another body, to replace the missing or damaged organ. One of the most important aspect of the organ transplantation is the consent of the patient himself or the family of the patient. Organ harvesting without proper consent is illegal and a massive crime. Organ transplantation is mostly carried out with the brain dead patient whose other organs are healthy and can be used to save another person’s life. The process of organ transplantation needs to be done right after the death of the patient until couple of hours. This procedure is performed to treat organ failures in lungs, liver, kidney, and many more. Kidney is the most widely transplanted organ which is followed by liver. Unfortunately, the need for organ donors is much higher than the number of people who donate organs. Organs most often transplanted include the kidney due to diabetes, polycystic kidney disease, lupus, or other problems. The liver because of cirrhosis, which has many causes. And heart because of coronary artery disease.

Get a sample report at .

The major driving factor for the organ transplantation market are increasing prevalence of number of chronic diseases and organ failure. Increasing prevalence of renal diseases, over consumption of alcohol and unhealthy diet has provided push for the growth of the market. Whereas, high cost of transplantation, limited number of donor and increasing incident of organ failure has restrained the growth of the market.

According to the National Kidney Foundation, more than 3,000 new patients are added to the kidney waiting list each month worldwide. According to United Network for organ sharing, in the United States everyday 21 people die waiting for an organ, and more than 120,000 men, women, and children await lifesaving organ transplants.

Global Organ Transplantation Market   – Competitive Analysis

Novartis International AG (Switzerland), Terumo Medical Corporation (U.S.), Transonic (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Astellas Pharma, Inc (Japan), Preservation Solutions, Inc. (U.S.),  OrganOX Limited (U.K), Bio Med Pvt. Ltd. (U.S.), Transplant Biomedical (U.K), TransMedic, Inc. (U.S.), Accord Healthcare GmbH (Spain), Sanofi (France), Pfizer, Inc. (U.S.), Veloxis Pharmaceuticals A/S (Denmark), GlaxoSmithKline Plc. (U.K) are some of the prominent players at the forefront of competition in the global organ transplantation market and are profiled in MRFR Analysis. 

June, 2017- Veloxis Pharmaceuticals A/S and Endo Ventures Limited jointly announced agreement for Paladin Labs Inc. to commercialize Envarsus XR in Canada. Envarsus XR (tacrolimus extended-release tablets) is a novel formulation of tacrolimus for the prophylaxis of organ rejection in kidney transplant patients. Currently Envarsus XR is approved in Europe and the United States. Canada is a highly competitive market for tacrolimus formulations and with this agreement with Endo Ventures Limited and its affiliate, Paladin Labs Inc., which has a rich history of Health Canada approvals and launches of licensed products for Canada, to boost the growing Envarsus XR market. Evenmore Veloxis Pharmaceuticals A/S announced agreement with Chiesi Farmaceutici S.p.A. to commercialize Envarsus XR in China also.

Oct, 2015- Astellas Pharma Canada, Inc. announced partnership with Canadian Society of Transplantation. Astellas provided important resources and programs that helped further research in solid organ transplantation. Astellas Pharma Inc., is based in Japan, and company is dedicated to improving the health of people globally through the provision of innovative and reliable pharmaceutical products. The company mainly focuses on urology, oncology, immunology, nephrology and neuroscience as prioritized therapeutic areas.

Browse Complete report at .

Global Organ Transplantation Market   – Regional Analysis

Geographically, Americas dominate the global organ transplantation market owing to increasing prevalence of organ failure, rapid development in the medical sector, well developed healthcare sectors and higher healthcare expenditure. As per reports from U.S. Government Information on Organ Donation and Transplantation, in the United States alone, 21 people die daily waiting for an organ transplant. Though about 45% of American adults are registered organ donors but it varies widely by state. More than 80% of adults in Alaska were registered donors in 2012, compared to only 12.7% in New York.

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India